Hologic Inc. (NASDAQ: HOLX) announced that Chief Executive Officer Steve MacMillan will retire when the company's go-private transaction with Blackstone and TPG closes, expected around April 7, 2026.

MacMillan has served as chairman, president and CEO for over 12 years since joining the medical technology company in December 2013. During his tenure, Hologic's revenue increased 65%, non-GAAP earnings per share rose 184%, and the company's workforce grew by more than 1,500 employees, according to the press release.

The transaction has received all required regulatory approvals and is scheduled to close on or about April 7, 2026. Hologic's next CEO is expected to be announced when the deal closes.

"Leading Hologic has been the greatest honor and privilege of my career," MacMillan said in the statement. "I'm immensely grateful to the customers and patients who trusted us, the board and investors who supported us, and especially the employees who made all our accomplishments possible."

Amy Wendell, Hologic's lead independent director, praised MacMillan's leadership, noting his role in the company's turnaround, growth trajectory, COVID-19 pandemic response, and guidance through the go-private transaction.

Before joining Hologic, the 62-year-old MacMillan served as president and CEO of Stryker from 2005 to 2012 and held senior executive positions at Pharmacia and Johnson & Johnson. He began his career at Procter and Gamble in 1985.

Hologic focuses on women's health technology, including early detection and treatment solutions. The company is being acquired by private equity firms Blackstone and TPG in a transaction that will take the publicly traded company private.